Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKeshu ZhouWLWei LiuYLYuhua Li

Discussion

Loading...

Member takes

Overview

Single-arm trial shows 96.4% best objective response in R/R indolent non-Hodgkin lymphoma, suggesting Axi-cel is an effective therapy.

Key Points

  • To evaluate the efficacy and safety of axicabtagene ciloleucel in treating relapsed or refractory indolent non-Hodgkin lymphomas in a Chinese population.
  • Conducted a single-arm, multicenter, phase 2 trial
  • Enrolled patients aged 18 and older with histologically confirmed iNHL
  • Primary endpoint was best objective response rate per Lugano classification
  • Achieved a 96.4% best objective response rate among evaluable patients
  • 74.1% had a complete response to treatment
  • Observed manageable safety profile with low incidence of severe adverse events.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d27bhttps://doi.org/10.1182/blood-2025-1796
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study2025
  2. 2Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025
  3. 3Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  4. 4Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  5. 5Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025